Bukstein Oscar
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, USA.
Medscape J Med. 2008 Jan 31;10(1):24.
Substance use disorder (SUD) is a common comorbidity of attention-deficit/hyperactivity disorder (ADHD) that is frequently seen during adolescence. Physicians who treat patients with ADHD need to be aware of both the behavioral and medical signs of substance abuse and closely screen their patients for SUD. Optimal treatment of the symptoms of ADHD is the most effective way to reduce the incidence of SUD, but the use of stimulants, the first-line therapy for ADHD, is associated with an appreciable degree of abuse and misuse of therapeutic drugs. Cardiovascular and psychiatric risks with ADHD drugs have resulted in recent labeling changes for these drugs. A correct diagnosis of ADHD is important in validating the use of stimulant medication. New strategies for effectively treating ADHD that may minimize the risk for drug abuse are being developed and include extended-release formulations of currently used drugs, new nonstimulant drugs for the treatment of ADHD, and novel prodrugs that optimize therapeutic plasma concentrations of drugs. Nonmedication or psychosocial treatments, especially for adult ADHD, are also available. Further assessment of these strategies should permit the development of new approaches to the treatment of ADHD that reduce the risk for abuse and misuse of stimulant medications.
物质使用障碍(SUD)是注意缺陷多动障碍(ADHD)常见的共病情况,在青少年时期较为常见。治疗ADHD患者的医生需要了解药物滥用的行为和医学体征,并对患者进行SUD的密切筛查。优化ADHD症状的治疗是降低SUD发生率的最有效方法,但作为ADHD一线治疗药物的兴奋剂,存在相当程度的治疗药物滥用和误用情况。ADHD药物带来的心血管和精神风险导致了这些药物近期的标签变更。正确诊断ADHD对于验证兴奋剂药物的使用至关重要。正在开发可能将药物滥用风险降至最低的有效治疗ADHD的新策略,包括现有药物的缓释制剂、治疗ADHD的新型非兴奋剂药物,以及优化药物治疗血浆浓度的新型前体药物。非药物或心理社会治疗方法也有,尤其是针对成人ADHD。对这些策略的进一步评估应有助于开发新的ADHD治疗方法,降低兴奋剂药物滥用和误用的风险。